Human Glial Chimeric Mouse Model for JC Virus Infection Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective animal models for studying human-specific glial infections, particularly for assessing drug candidates against progressive multifocal leukoencephalopathy (PML) caused by the JC virus, due to the virus's selective infectivity and pathology in humans.
Innovation Solution
A human glial chimeric model is created by engrafting immunodeficient mice with human glial progenitor cells, allowing for the assessment of JC virus infection and demyelination, and evaluating potential therapeutic agents in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional animal models are used to study JC virus infection, then the model is simple to establish and maintain, but the virus cannot infect the animals due to species-specific restrictivity
Solution Approach 1:
Human glial progenitor cells serve as an intermediary between the JC virus and the mouse host. These human-derived cells are transplanted into immunodeficient mice, creating a bridge that allows the human-specific virus to infect and replicate within a human cellular environment while maintaining the advantages of an animal model system.
Solution Approach 2:
The model combines three distinct components: human glial progenitor cells (biological material), immunodeficient mice (host organism), and JC virus (pathogen). This composite system integrates human cellular specificity with animal model tractability, enabling reliable infection studies while managing complexity through the use of immunodeficient hosts that accept human cell grafts.
2Reliability
If human glial chimeric models are created to enable JC virus infection, then the infection capability and pathogenicity assessment are improved, but the model complexity and establishment difficulty increase
Solution Approach 1:
The mice are pre-engineered with immunodeficiency mutations (rag2â/â and shi/shi) before receiving human glial progenitor cell transplants. This preliminary modification of the host immune system ensures that the subsequent human cell engraftment will be accepted and maintained, facilitating the creation of functional chimeric models without complex post-transplant immunosuppression protocols.
3Loss of information
If human glial progenitor cells are transplanted into immunodeficient mice, then the in vivo human glial cell response to infection can be assessed, but the time and resources required for model development increase
Solution Approach 1:
The human glial progenitor cells, once transplanted into the immunodeficient mice, autonomously differentiate into mature glial cells and establish functional tissue within the host brain. This self-organizing capability of the transplanted cells reduces the need for external intervention and accelerates model maturation, allowing researchers to assess human glial responses to infection without extensive manual manipulation or long cultivation periods.
Data Source
AI summary
The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.